English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome- positive acute lymphoblastic leukemia requries IKAROS function

Trageser, D., Iacobucci, I., Nahar, R., Duy, C., von Levetzow, G., Klemm, L., et al. (2009). Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome- positive acute lymphoblastic leukemia requries IKAROS function. The Journal of Experimental Medicine, 206, 1739-1753.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Trageser, Daniel, Author
Iacobucci, Ilaria, Author
Nahar, Rahul, Author
Duy, Cihangir, Author
von Levetzow, Gregor, Author
Klemm, Lars, Author
Park, Eugene, Author
Schuh, Wolfgang, Author
Gruber, Tanja, Author
Herzog, Sebastian1, Author           
Kim, Yong-mi, Author
Hofmann, Wolf-Karsten, Author
Li, Aihong, Author
Storlazzi, Clelia Tiziana, Author
Jäck, Hans-Martin, Author
Groffen, John, Author
Martinelli, Giovanni, Author
Heisterkamp, Nora, Author
Jumaa, Hassan1, Author           
Müschen, Markus, Author
Affiliations:
1Research Group and Chair of Molecular Immunology of the University of Freiburg, Max Planck Institute of Immunobiology and Epigenetics, Max Planck Society, ou_2243645              

Content

show
hide
Free keywords: -
 Abstract: B cell lineage acute lymphoblastic leukemia (ALL) arises in virtually all cases from B cell precursors that are arrested at pre-B cell receptor-dependent stages. The Philadelphia chromosome-positive (Ph+) subtype of ALL accounts for 25-30% of cases of adult ALL, has the most unfavorable clinical outcome among all ALL subtypes and is defined by the oncogenic BCR-ABL1 kinase and deletions of the IKAROS gene in >80% of cases. Here, we demonstrate that the pre-B cell receptor functions as a tumor suppressor upstream of IKAROS through induction of cell cycle arrest in Ph+ ALL cells. Pre-B cell receptor-mediated cell cycle arrest in Ph+ ALL cells critically depends on IKAROS function, and is reversed by coexpression of the dominant-negative IKAROS splice variant IK6. IKAROS also promotes tumor suppression through cooperation with downstream molecules of the pre-B cell receptor signaling pathway, even if expression of the pre-B cell receptor itself is compromised. In this case, IKAROS redirects oncogenic BCR-ABL1 tyrosine kinase signaling from SRC kinase-activation to SLP65, which functions as a critical tumor suppressor downstream of the pre-B cell receptor. These findings provide a rationale for the surprisingly high frequency of IKAROS deletions in Ph+ ALL and identify IKAROS-mediated cell cycle exit as the endpoint of an emerging pathway of pre-B cell receptor-mediated tumor suppression.

Details

show
hide
Language(s): eng - English
 Dates: 2009
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 466122
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: The Journal of Experimental Medicine
  Alternative Title : JEM
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 206 Sequence Number: - Start / End Page: 1739 - 1753 Identifier: -